{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:57:51Z","timestamp":1770292671922,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2019.04.028","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T23:09:31Z","timestamp":1560899371000},"page":"4204-4213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines"],"prefix":"10.1016","volume":"37","author":[{"given":"Cristina","family":"Manara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Brazzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Piccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Taccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"D'Oro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Maione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8173-3788","authenticated-orcid":false,"given":"Elisabetta","family":"Frigimelica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.028_b0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.smim.2013.05.001","article-title":"RNA: the new revolution in nucleic acid vaccines","volume":"25","author":"Geall","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2019.04.028_b0010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14712598.4.8.1285","article-title":"Messenger RNA-based vaccines","volume":"4","author":"Pascolo","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2019.04.028_b0015","doi-asserted-by":"crossref","first-page":"44148","DOI":"10.1016\/j.vaccine.2012.04.060","article-title":"RNA-based vaccines","volume":"30","author":"Ulmer","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.028_b0020","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.028_b0025","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2019.04.028_b0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.04.028_b0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.29402","article-title":"A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile","volume":"137","author":"Heidenreich","year":"2015","journal-title":"Int J Cancer J Int du Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.028_b0040","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/17425247.2014.901308","article-title":"Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines","volume":"11","author":"Deering","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2019.04.028_b0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2016.05.008","article-title":"Recent innovations in mRNA vaccines","volume":"41","author":"Ulmer","year":"2016","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1517\/17460441.2015.996128","article-title":"Vaccines 'on demand': science fiction or a future reality","volume":"10","author":"Ulmer","year":"2015","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.028_b0055","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.4161\/hv.25181","article-title":"A novel, disruptive vaccination technology: self-adjuvanted RNActive(\u00ae) vaccines","volume":"9","author":"Kallen","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"10.1016\/j.vaccine.2019.04.028_b0060","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1016\/j.vaccine.2016.05.046","article-title":"Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity","volume":"34","author":"Kowalczyk","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.028_b0070","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/vaccines1030367","article-title":"Enhanced delivery and potency of self-amplifying mRNA vaccines by electroporation in situ","volume":"1","author":"Cu","year":"2013","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.028_b0075","doi-asserted-by":"crossref","first-page":"e0161193","DOI":"10.1371\/journal.pone.0161193","article-title":"Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge","volume":"11","author":"Magini","year":"2016","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.028_b0080","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin","volume":"90","author":"Brazzoli","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.028_b0085","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1038\/emi.2013.54","article-title":"Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice","volume":"2","author":"Hekele","year":"2013","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/imm.12505","article-title":"CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes","volume":"146","author":"Lazzaro","year":"2015","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.vaccine.2019.04.028_b0095","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1128\/JVI.02564-07","article-title":"Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation","volume":"82","author":"Liu","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.1874","article-title":"Rational design of gene-based vaccines","volume":"208","author":"Barouch","year":"2006","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.028_b0105","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1021\/bm501166j","article-title":"In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice","volume":"15","author":"Liu","year":"2014","journal-title":"Biomacromolecules"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.028_b0110","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1172\/JCI200422608","article-title":"Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines","volume":"114","author":"Sumida","year":"2004","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2019.04.028_b0115","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/eji.200324840","article-title":"Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses","volume":"34","author":"McKay","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.028_b0120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-1-4615-1971-3_127","article-title":"Vaccine adjuvancy: a new potential area of development for GM-CSF","volume":"378","author":"Taglietti","year":"1995","journal-title":"Adv Exp Med Biol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2019.04.028_b0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01973602","article-title":"Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant","volume":"13","author":"Jones","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.028_b0130","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00062752-200005000-00007","article-title":"Uses of granulocyte-macrophage colony-stimulating factor in vaccine development","volume":"7","author":"Warren","year":"2000","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.028_b0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF01971991","article-title":"The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: a commentary","volume":"13","author":"Bodey","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.028_b0140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C","article-title":"Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo","volume":"67","author":"J\u00e4ger","year":"1996","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.028_b0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood.V88.1.202.202","article-title":"Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines","volume":"88","author":"Disis","year":"1996","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.vaccine.2019.04.028_b0150","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0264-410X(96)00031-X","article-title":"Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine","volume":"14","author":"Tarr","year":"1996","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.028_b0155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(92)90678-5","article-title":"Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia","volume":"93","author":"Kurzrock","year":"1992","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.028_b0160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.1991.tb08573.x","article-title":"Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes","volume":"77","author":"Estey","year":"1991","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.04.028_b0165","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood.V93.8.2653","article-title":"Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor","volume":"93","author":"McNeel","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vaccine.2019.04.028_b0170","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/(SICI)1521-4141(199806)28:06<1832::AID-IMMU1832>3.0.CO;2-J","article-title":"Immunological memory after somatic transgene immunization is positively affected by priming with GM-CSF and does not require bone marrow-derived dendritic cells","volume":"28","author":"Gerloni","year":"1998","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.028_b0175","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.1128\/JVI.72.10.8430-8436.1998","article-title":"Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene","volume":"72","author":"Lee","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0180","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1074-7613(95)80001-8","article-title":"Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines","volume":"2","author":"Xiang","year":"1995","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0185","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4049\/jimmunol.158.2.816","article-title":"In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen","volume":"158","author":"Kim","year":"1997","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2019.04.028_b0190","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.4049\/jimmunol.158.10.4591","article-title":"Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines","volume":"158","author":"Iwasaki","year":"1997","journal-title":"J Immunol"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2019.04.028_b0195","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0264-410X(98)00333-8","article-title":"Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization","volume":"17","author":"Cho","year":"1999","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.04.028_b0200","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.4049\/jimmunol.161.5.2325","article-title":"A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine","volume":"161","author":"Weiss","year":"1998","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.028_b0205","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.4049\/jimmunol.158.3.1231","article-title":"Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids","volume":"158","author":"Geissler","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.028_b0210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4049\/jimmunol.162.1.168","article-title":"Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage","volume":"162","author":"Labeur","year":"1999","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.028_b0215","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2019.04.028_b0220","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4049\/jimmunol.163.1.174","article-title":"Transfection of immature murine bonemarrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity","volume":"163","author":"Curiel-Lewandrowski","year":"1999","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2019.04.028_b0225","doi-asserted-by":"crossref","first-page":"14266","DOI":"10.1016\/S0021-9258(19)49707-X","article-title":"Requirement of hydrophilic amino-terminal residues for granulocyte-macrophage colony-stimulating factor bioactivity and receptor binding","volume":"267","author":"Meropol","year":"1992","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2019.04.028_b0230","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1128\/JVI.72.7.5648-5653.1998","article-title":"Protective CD4+ and CD8+ T-cells against influenza virus induced by vaccination with nucleoprotein DNA","volume":"72","author":"Ulmer","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.04.028_b0235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1084\/jem.188.2.223","article-title":"Contribution of virus-specific CD8+ cytotoxic T-cells to virus clearance or pathologic manifestations of influenza virus infection in a T-cell receptor transgenic mouse model","volume":"188","author":"Moskophidis","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.04.028_b0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.virol.2017.11.018","article-title":"A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model","volume":"515","author":"Herrera-Rodriguez","year":"2018","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.028_b0245","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2019.04.028_b0250","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol Ther"},{"issue":"13","key":"10.1016\/j.vaccine.2019.04.028_b0255","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.vaccine.2015.02.019","article-title":"Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T-cells and enhances dendritic cell cross-presentation","volume":"33","author":"Lee","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2019.04.028_b0260","doi-asserted-by":"crossref","first-page":"e1003467","DOI":"10.1371\/journal.ppat.1003467","article-title":"Emerging infectious diseases: threats to human health and global stability","volume":"9","author":"Morens","year":"2013","journal-title":"PLoS Pathog"},{"issue":"9","key":"10.1016\/j.vaccine.2019.04.028_b0265","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.04.028_b0270","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.4049\/jimmunol.178.3.1285","article-title":"An in vivo cytotoxicity threshold for influenza A virus-specific effector and memory CD8(+) T-cells","volume":"178","author":"Stambas","year":"2007","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T15:18:45Z","timestamp":1694963925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19304797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X19304797"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}